Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) ...

Researchers from the Institute of Cancer Research (ICR) have found that prostate cancer patients with high levels of a ...

Novo Nordisk and NanoVation Therapeutics have entered into a multi-year partnership worth $600m to advance genetic medicines ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Wedgewood Communications has appointed Danielle Cranwell as president and global agency head to lead the evolution of the agency’s strategic vision and future direction. Cranwell brings more than two ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC) met its primary endpoint ...

Post-treatment follow-up of patients is not new. Traditional follow-up studies may last two to five years, while long-term follow-up (LTFU) studies can last from 15 years to a lifetime. Cell and gene ...

Roche’s injectable monoclonal antibody Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) has been approved by the US Food and Drug Administration (FDA) to treat both relapsing and primary ...

Johnson & Johnson’s (J&J) Rybrevant (amivantamab-vmjw) combination has demonstrated a positive overall survival trend in adults with lung cancer, according to new late-stage results shared by the ...